Sheheryar Kabraji

11PUBLICATIONS
83CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)MechanobiologyCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Apr 27, 2026
The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond.

|Jan 23, 2026
Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 Inhibitors.

Thomas N O'Connor, Emily Schultz, Sheheryar Kabraji

|Jun 08, 2024
Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer.

Albert Grinshpun, Douglas Russo, Wen Ma

|Feb 12, 2024
RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer.

Harshabad Singh, Pranshu Sahgal, Kevin Kapner

|Jun 12, 2023
Keeping It in the Family: HER3 as a Target in Brain Metastases.

Sheheryar Kabraji, Nancy U Lin

|Apr 19, 2023
PI3Kβ controls immune evasion in PTEN-deficient breast tumours.

Johann S Bergholz, Qiwei Wang, Qi Wang

Pageof 2

Frequent Collaborators

5 joint publications

Jean J Zhao

3 joint publications

Johann S Bergholz

2 joint publications

Qiwei Wang

2 joint publications

Hye-Jung Kim